OXiGENE appoints Fred Driscoll to its Board of Directors as Chairman

– USA, CA –OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the appointment of Frederick W. Driscoll to its board of directors, effective January 1, 2014. Mr. Driscoll is a respected executive and financial management expert with more than 30 years of experience in the biotechnology and medical device industries. Mr. Driscoll will assume the role of Chairman of the OXiGENE board of directors and will also serve on the audit committee.

“The OXiGENE management team and board welcome Fred back to our company, and are looking forward to benefitting from his many years of executive experience in growing companies in our industry and helping them to achieve their corporate goals and solidify their market positions,” said Peter Langecker, M.D., Ph.D., OXiGENE’s Chief Executive Officer. “Fred joins our board at an important time in our development, as vascular disrupting agents are beginning to achieve clinical validation, and our programs are potentially advancing toward registration. We welcome his leadership and strategic vision.”

Mr. Driscoll currently serves as Chief Financial Officer of Flexion Therapeutics. Prior to joining Flexion, Mr. Driscoll was Chief Financial Officer for Novavax Inc., and earlier served as Chief Executive Officer of Genelabs Technologies, where he oversaw the sale of Genelabs to GlaxoSmithKline. Prior to his position at Genelabs, Mr. Driscoll served in a variety of financial and senior management positions at Astraris, Inc. and Collagenesis Corp. He also spent more than twenty years with Instrumentation Laboratory as vice president of finance for the Americas. From 2002 – 2006, Mr. Driscoll served as President and Chief Executive Officer of OXiGENE. Mr. Driscoll holds a bachelor’s degree in accounting and finance from Bentley University in Waltham, MA.


OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. The Company’s lead clinical product, ZYBRESTAT, is in development as a potential treatment for ovarian cancer and anaplastic thyroid cancer (ATC). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team